Invesco Reports $1.8B Intangible Impairment Leading to GAAP Loss, Offset by Strong AUM Growth and Adjusted EPS
IVZ has more than doubled off its 52-week low of $11.6.
Summary
Invesco Ltd. reported a Q4 2025 GAAP diluted EPS loss of $(2.61) due to a $1.8 billion non-cash intangible asset impairment, but delivered strong adjusted diluted EPS of $0.62 and record AUM of $2.2 trillion driven by significant net long-term inflows.
Key Events · Earnings and Guidance · IVZ
-
Significant Intangible Impairment
Incurred a $1.8 billion non-cash intangible asset impairment in Q4 2025, leading to a GAAP diluted EPS of $(2.61) for the quarter.
-
Strong Adjusted Earnings
Reported adjusted diluted EPS of $0.62 for Q4 2025, a slight increase from $0.61 in the prior quarter and $0.52 in Q4 2024.
-
Record AUM and Net Inflows
Achieved $2.2 trillion in ending AUM, an increase of 17.5% from the prior year-end, driven by $19.1 billion in net long-term inflows for Q4 2025 and $81.2 billion for the full year.
-
Balance Sheet Strengthening
Repurchased $500 million of outstanding Series A Preferred Stock and repaid the remaining $240 million of a 3-year bank term loan during the quarter.
Analysis · IVZ · Finance
Invesco Ltd. reported a significant non-cash intangible asset impairment of $1.8 billion in Q4 2025, resulting in a GAAP diluted EPS loss of $(2.61). This impairment primarily relates to prior acquisitions of U.S. retail mutual fund management contracts, indicating a re-evaluation of these asset values. Despite the GAAP loss, the company demonstrated strong operational performance with adjusted diluted EPS of $0.62, a slight increase from the previous quarter. The asset manager also achieved record ending Assets Under Management (AUM) of $2.2 trillion, marking a 17.5% increase year-over-year, fueled by robust net long-term inflows of $19.1 billion for the quarter and $81.2 billion for the full year. Furthermore, Invesco strengthened its balance sheet by repurchasing $500 million of preferred stock and repaying $240 million of debt. While the impairment is a notable negative, the underlying business momentum in AUM growth, inflows, and adjusted profitability, coupled with balance sheet improvements, presents a mixed but operationally strong picture for the company, which is currently trading near its 52-week high.
At the time of this filing, IVZ was trading at $29.11 on NYSE in the Finance sector, with a market capitalization of approximately $12.7B. The 52-week trading range was $11.60 to $29.61. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.